3a,4,7,7a-四氢-4,7-亚甲基-1H-茚基甲丙烯酰酸酯 | 98633-82-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3a,4,7,7a-四氢-4,7-亚甲基-1H-茚基甲丙烯酰酸酯
• 英文名称: Tripalmitoyl-s-glyceryl-cysteinyl-seryl-serine
• 英文别名: (2S)-2-[[(2S)-2-[[(2R)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoic acid
• CAS: 98633-82-0
• 化学式: C₆₀H₁₁₃N₃O₁₁S
• 分子量: 1084.6
• InChiKey: XVQKZSLOGHBCET-INVHGPFASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  19
• 重原子数：
  75
• 可旋转键数：
  59
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  243
• 氢给体数：
  6
• 氢受体数：
  12

文献信息

• Cancer vaccine vesicles
  申请人：Bestewil Holding B.V.

  公开号：EP1666056A1

  公开（公告）日：2006-06-07

  The present invention relates to methods for producing a membranous vesicle with a diameter at least 25 nm in and a lipid bilayer which comprises a viral fusion protein and tumour cell membrane components that are capable of eliciting an antitumour response. Preferably the lipid bilayer of the vesicles further comprises an amphiphilic adjuvant. The invention further relates to membranous vesicles obtainable in the methods of the invention, pharmaceutical composition comprising such vesicles as well as methods for immunisation against tumours in which the vesicle are used.

  本发明涉及生产直径至少为 25 nm 的膜囊泡和脂质双分子层的方法，该膜囊泡和脂质双分子层包括能够引起抗肿瘤反应的病毒融合蛋白和肿瘤细胞膜成分。囊泡的脂质双分子层最好还包括一种两性佐剂。本发明还涉及可通过本发明方法获得的膜囊泡，包含这种囊泡的药物组合物，以及使用这种囊泡的肿瘤免疫方法。
• Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
  申请人：Bestewil Holding B.V.

  公开号：EP2058002A1

  公开（公告）日：2009-05-13

  The invention relates to reconstituted membranes of Respiratory Syncytial Virus. The invention also relates to a vaccine for Respiratory Syncytial Virus. The invention further relates to methods of production of virosomes comprising reconstituted Respiratory Syncytial virus membranes.

  本发明涉及呼吸道合胞病毒的重组膜。本发明还涉及呼吸道合胞病毒疫苗。本发明还涉及由重组呼吸道合胞病毒膜组成的病毒体的生产方法。
• Functionally reconstituted viral membranes containing adjuvant
  申请人：Bestewil Holding B.V.

  公开号：EP2368576A2

  公开（公告）日：2011-09-28

  The present invention relates to vaccines directed against antigens such as membrane proteins from pathogens or tumor cells. The invention further relates to methods of forming reconstituted viral membranes, with membrane fusion activity, which are lipid bilayer membranes preferably containing natural lipids of a virus, a viral fusion protein, one or more optional further antigens as well as amphiphilic adjuvants. Pharmaceutical compositions comprising such reconstituted viral membranes are also part of the invention.

  本发明涉及针对病原体或肿瘤细胞的膜蛋白等抗原的疫苗。本发明还涉及形成具有膜融合活性的重组病毒膜的方法，重组病毒膜是脂质双层膜，最好含有病毒的天然脂质、病毒融合蛋白、一种或多种可选的进一步抗原以及两性佐剂。包含这种重组病毒膜的药物组合物也是本发明的一部分。
• Viral vaccine composition, process, and methods of use
  申请人：——

  公开号：US20030092145A1

  公开（公告）日：2003-05-15

  A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.

  本文描述了一种用于治疗或预防病毒引起的感染的组合物，以及该组合物的生产过程和使用方法。该组合物由受病毒病原体感染的细胞或组织，或恶性或免疫异常的细胞或组织组成，这些细胞或组织已被还原和/或变性。优选的组合物在遭受或即将遭受感染的动物粘膜表面给药。组合物可作为预防或治疗疫苗使用。
• Functionallly reconstituted viral membranes containing adjuvant
  申请人：Stegmann Johannes Hendrikus Antonius

  公开号：US20060193873A1

  公开（公告）日：2006-08-31

  The present invention relates to vaccines directed against antigens such as membrane proteins from pathogens or tumor cells. The invention further relates to methods of forming reconstituted viral membranes, with membrane fusion activity, which are lipid bilayer membranes preferably containing natural lipids of a virus, a viral fusion protein, one or more optional further antigens as well as amphiphilic adjuvants. Pharmaceutical compositions comprising such reconstituted viral membranes are also part of the invention.

  本发明涉及针对病原体或肿瘤细胞的膜蛋白等抗原的疫苗。本发明还涉及形成具有膜融合活性的重组病毒膜的方法，重组病毒膜是脂质双层膜，最好含有病毒的天然脂质、病毒融合蛋白、一种或多种可选的进一步抗原以及两性佐剂。包含这种重组病毒膜的药物组合物也是本发明的一部分。